Business
Medical City Dallas Hospital Adopts Perimeter's Innovative OCT Imaging Technology for Surgery
Medical City Dallas Hospital Adopts Perimeter's Innovative OCT Imaging Technology for Surgery ...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n\n\n\n Medical City Dallas Hospital Adopts Perimeter's Innovative OCT Imaging Technology for Surgery\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n\n\n\n\n\n Deployment follows participation in pivotal trial of Perimeter's next-gen technology with AI for breast-conserving surgeries\n \n\n\n\n\n TORONTO\n \n and\n \n DALLAS\n \n\n ,\n \n\n July 2, 2025\n \n\n /CNW/ -\n \n Perimeter Medical Imaging AI, Inc.\n \n (TSXV: PINK) (OTCQX: PYNKF) (\"Perimeter\" or the \"Company\"), a commercial-stage medical technology company, announced today that\n \n Medical City Dallas Hospital\n \n , an award-winning 899-bed acute care hospital in the\n \n Dallas-Fort Worth\n \n area, has adopted the company's current\n \n S-Series OCT\n \n (optical coherence tomography) technology for high-resolution visualization of tissue microstructures during surgery. The move comes on the heels of the hospital's participation in the pivotal, randomized controlled trial of\n \n Perimeter's next-generation B-Series device,\n \n which combines proprietary artificial intelligence (\"AI\") technology with OCT, and is being evaluated by the U.S. Food and Drug Administration for use during breast-conserving surgeries in\n \n the United States\n \n .\n \n\n \"We are incredibly proud to partner with Medical City Dallas Hospital and its team of surgeons, who are truly innovators in their field,\" said Perimeter CEO\n \n Adrian Mendes\n \n . \"Working with Dr. DiPasquale and Dr. Anderson and the Medical City Dallas team, who used our B-Series in the randomized controlled pivotal trial, has been invaluable to advancing our next-generation product and we are pleased that they are adopting our commercially approved S-Series to potentially enhance margin visualization in the OR.\"\n \n\n Medical City Dallas Hospital is the latest U.S. hospital to adopt the S-Series OCT, as Perimeter continues to deploy the technology nationwide. Cleared by the U.S. Food and Drug Administration (FDA) in 2021 for a general tissue indication, S-Series OCT is a hi...